{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:27:10Z","timestamp":1794533230372,"version":"4.9.1"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":172,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.prdoa.2026.100475","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:22:50Z","timestamp":1782231770000},"page":"100475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Successful use of continuous subcutaneous Foslevodopa\/Foscarbidopa in Parkinson's disease with bipolar disorder without psychiatric destabilization"],"prefix":"10.1016","volume":"15","author":[{"given":"Joanna","family":"Siuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Gawryluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Krupczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"To\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2026.100475_bb0005","first-page":"66","article-title":"Association between bipolar disorder and Parkinson\u2019s disease","volume":"35","author":"Merxem","year":"2023","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.prdoa.2026.100475_bb0010","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance","volume":"10","author":"VSC","year":"2024","journal-title":"Clin. Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2026.100475_bb0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5603\/pjnns.109897","article-title":"Infusion therapies for advanced Parkinson\u2019s disease: current evidence and practical challenges \u2014 a narrative review","volume":"60","author":"To\u015b","year":"2026","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.prdoa.2026.100475_bb0020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mdc3.70060","article-title":"Cognitive and psychiatric adverse effects of Foslevodopa\/Foscarbidopa in patients with Parkinson\u2019s disease","volume":"12","author":"Broh\u00e9e","year":"2025","journal-title":"Mov. Disord Clin. Pract."},{"key":"10.1016\/j.prdoa.2026.100475_bb0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14802\/jmd.25304","article-title":"Neuropsychiatric and cognitive safety of subcutaneous Foslevodopa\/Foscarbidopa in advanced Parkinson\u2019s disease: insights from a real-world cohort","volume":"19","author":"Desjardins","year":"2026","journal-title":"J. Movement Disorders"},{"key":"10.1016\/j.prdoa.2026.100475_bb0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5603\/pjnns.107127","article-title":"New-onset psychotic symptoms following continuous dopaminergic stimulation with subcutaneous foslevodopa\/foscarbidopa","volume":"59","author":"To\u015b","year":"2025","journal-title":"Neurol. Neurochir. Pol."}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112526000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:00:43Z","timestamp":1794531643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112526000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":6,"alternative-id":["S2590112526000551"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100475","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of continuous subcutaneous Foslevodopa\/Foscarbidopa in Parkinson's disease with bipolar disorder without psychiatric destabilization","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2026.100475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100475"}}